Satirapoj B, et al. - Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown recently to exert renoprotection beyond glycemic control in people with type 2 diabetes (T2DM), researchers assessed the impact of SGLT2 inhibitors on proximal tubular injury and function in patients with T2DM and persistent glycated hemoglobin (HbA1c) levels > 7%. Study participants were randomly assigned to either dapagliflozin 10 mg/day (n=28) or standard treatment (n=29) for 12 weeks, with comparable baseline characteristics between treatment groups. Proximal tubular injury biomarkers were assessed at baseline and study end. The investigators observed a renoprotective effect of dapagliflozin in patients with T2DM. Twelve weeks of dapagliflozin treatment vs standard-treatment resulted in reductions in HbA1c (–0.75 ± 0.21 vs –0.70 ± 0.25%; P=0.882). With regard to the reduction in urine albumin:creatinine ratio and urine kidney injury molecule-1:creatinine ratio, significant between-group differences were observed. However, changes in urine cystatin C:creatinine ratio did not show significant difference between the two groups. Overall, SGLT2 inhibitors could have utility in the treatment of T2DM by protecting against renal tubular injury and may lead to reduced long-term renal outcomes.